
    
      This is an in-clinic, multi-center, randomized, double-blind, placebo-controlled study of 2
      dose levels of Staccato Loxapine, 5 and 10 mg. Patients may receive up to 3 doses of study
      drug in a 24-hour period, depending on their clinical status. The primary endpoint is the
      change from baseline in the PANSS (Positive and Negative Symptom Scale) Excited Component
      (also known as PEC) score, performed at 2 hours after the first dose.
    
  